Englander Institute for Precision Medicine
EIPM Scientific Director Massimo Cristofanilli M.D.

A large prospective randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistant mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

The SERENA-6 study, published June 1 in the New England Journal of Medicine and presented concurrently at...

Credit: Cancer Cell

June 2025 EIPM Director's Memo


Dear Friends & Members of the Englander Institute,

I hope you enjoy reading about our recent departmental accomplishments, including news media coverage of our work, participation in major conferences & meetings, and impressive publications in top-tier journals like The New England Journal of MedicineNature Communications, and Science Signalingby a range of EIPM colleagues.

Thank you again...

New England Journal of Medicine AI

Dear Friends & Members of the Englander Institute,

ImagePlease join me in congratulating our Clinical Director Dr. Cora N. Sternberg on her ...